High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects

• Published in: Frontiers in immunology Vol. 11; p. 1660
• Main Authors: Liu, Xiaosheng, Cao, Wei, Li, Taisheng
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14.07.2020
• Subjects: Adult; Animals; Antibodies, Neutralizing - administration & dosage; Antibodies, Neutralizing - therapeutic use; Antibody-Dependent Enhancement; Betacoronavirus - immunology; Child; Coronavirus Infections - drug therapy; Coronavirus Infections - immunology; Coronavirus Infections - virology; COVID-19; Cytokines - metabolism; Humans; Immunoglobulin Fab Fragments - metabolism; Immunoglobulin Fc Fragments - metabolism; Immunoglobulin G - administration & dosage; Immunoglobulin G - therapeutic use; Immunoglobulins, Intravenous - administration & dosage; Immunoglobulins, Intravenous - therapeutic use; Immunologic Factors - administration & dosage; Immunologic Factors - therapeutic use; Immunology; intravenous immunoglobulin; mechanism of action; Pandemics; Pneumonia, Viral - drug therapy; Pneumonia, Viral - immunology; Pneumonia, Viral - virology; SARS-CoV-2; therapeutic inference; viral pneumonia; COVID-19; mechanism of action; SARS-CoV-2; therapeutic inference; intravenous immunoglobulin; viral pneumonia

The current outbreak of viral pneumonia, caused by novel coronavirus SARS-CoV-2, is the focus of worldwide attention. The WHO declared the COVID-19 outbreak a pandemic event on Mar 12, 2020, and the number of confirmed cases is still on the rise worldwide. While most infected individuals only experi...